Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Smoking compromises functional outcomes after acute ischaemic stroke

09 Jan 2020

Acute ischaemic stroke patients who are current or recent smokers are at greater odds of having unfavourable functional outcomes 3 months after the index event, a study has found.

Researchers looked at 10,825 patients (mean age, 70.2 years; 37.0 percent female) with acute ischaemic stroke who had been independent before stroke onset. Of the patients, 4,396 (42.7 percent) had never smoked (nonsmokers), 3,328 (32.4 percent) were former smokers and 2,561 (24.9 percent) were current smokers.

Multivariable logistic regression analysis showed that compared with nonsmokers, current but not former smokers had poorer functional outcome (modified Rankin Scale score ≥2) at 3 months. The corresponding odds ratios (ORs) were 1.29 (95 percent confidence interval [CI], 1.11–1.49) and 1.05 (95 percent CI, 0.92–1.21).

Among the former smokers, those who quit smoking within 2 years of stroke onset had a higher likelihood of having poor functional outcome at 3 months relative to nonsmokers (OR, 1.75, 95 percent CI, 1.15–2.66). Of note, the odds of poor functional outcome tended to increase with greater number of daily cigarettes used (p-trend=0.002).

The same pattern of associations was observed for functional dependence (modified Rankin Scale score 2–5).

Given the findings, smoking cessation should be urged not only from the standpoint of averting the development or recurrence of stroke but also to improve poststroke functional restoration and outcome, according to the researchers.

Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

3 days ago
Among individuals with abdominal obesity, drinking beverages with artificial sweeteners (ASBs) or no sugar (USBs) instead of sugar-sweetened beverages (SSBs) helps lose body weight, a study has found. However, USBs have a more favourable effect on sweet taste preference compared with ASBs.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.